ScientiaLux
Index
QF-Pro Home › QF-Pro Glossary › CAR T Cells
Cell Therapy

CAR T Cells

Engineered T cells redirected against cancer–where FRET could assess target engagement and off-tumor binding.

View
Definition
CAR T cells are patient-derived T cells genetically modified to express chimeric antigen receptors–synthetic receptors combining antibody-derived targeting domains with T cell signaling domains. FDA-approved CAR T products target CD19 (B cell malignancies) and BCMA (myeloma). A key challenge is "on-target, off-tumor" toxicity when CAR targets are expressed on normal tissues. FRETLoading...-based assessment of CAR-target engagement could help evaluate specificity before clinical use.
Engineered T Cells
Synthetic receptors
Tumor Targeting
Antibody-derived binding
FDA Approved
CD19, BCMA indications
Toxicity Risk
On-target, off-tumor

CAR T Engineering

CAR constructs contain: (1) an extracellular antigen-binding domain (typically scFv), (2) a hinge/transmembrane region, and (3) intracellular signaling domains (CD3ζ + costimulatory domains like 4-1BB or CD28). Upon antigen binding, CAR engagement triggers T cell activation independent of MHC.

This MHC-independent killing enables CAR T cells to attack tumors that have downregulated MHC–a common immune evasion mechanism. But the lack of central tolerance mechanisms that normally prevent autoimmunity creates toxicity risks.

Simplified

How It Works: A patient's T cells are removed, genetically modified to recognize cancer (by adding a chimeric antigen receptor), grown in large numbers, and infused back.

Success Stories: CAR-T has produced remarkable responses in certain blood cancers, including patients who had failed all other treatments.

FRET for CAR Validation

A challenge in CAR T development is predicting off-tumor binding before patient infusion. If CAR targets are expressed on normal tissues, serious toxicity can result. FRETLoading...-based assessment of CAR-target interaction in tissue samples could evaluate specificity.

As noted in the FEBS Letters review, "iFRET can be exploited for assessing precisely whether CAR T cells have associated with their malignant target as opposed to associating with their target antigen expressed by non-malignant cells."

Simplified

Potential Applications: FRET technology could potentially:

• Assess quality of CAR-target binding

• Measure checkpoint engagement on infiltrating CAR-T cells

• Help understand CAR-T exhaustion mechanisms

Status: These are theoretical applications for understanding CAR-T biology.

QF-Pro Application

Exploratory

Theoretical Application: CAR-T therapy involves engineered immune synapse formation. QF-Pro's iFRET methodology could theoretically assess CAR-target engagement quality and checkpoint engagement on infiltrating CAR-T cells.

Status: Theoretical application for CAR-T biology and persistence studies.

Note: This represents a theoretical application based on validated QF-Pro principles. Clinical validation studies are pending. See QF-Pro ApplicationsLoading... for validated targets.
Simplified

Future potential: CAR-T cells form engineered immune synapses. QF-Pro could assess CAR-target engagement quality and checkpoint upregulation that leads to exhaustion.

Applications of Functional Imaging in CAR T

  • Target validation: Confirm CAR binding specificity in tumor vs. normal tissue
  • Off-tumor assessment: Identify potential toxicity before patient treatment
  • Persistence monitoring: Assess CAR T engagement over timeLoading... post-infusion
  • Resistance mechanisms: Evaluate antigen loss or CAR dysfunction

Connected Terms

Share This Term
Term Connections